PE-22-28 vs Cartalax
Side-by-side comparison of key properties, dosing, and research.
- Summary
- PE-22-28 is a synthetic analog of spadin derived from sortilin, designed to block TREK-1 potassium channels with rapid-onset antidepressant and neurogenic effects. It shows fast-acting depression relief (within 24 hours) and promotes hippocampal neurogenesis.
- Cartalax is a tetrapeptide bioregulator (Ala-Glu-Asp-Pro) developed by Professor Vladimir Khavinson for cartilage and connective tissue. It is tissue-specific for chondrocytes and cartilaginous structures, supporting cartilage matrix synthesis, slowing degenerative changes, and promoting joint longevity. It is used in the context of osteoarthritis, joint aging, and athletic cartilage preservation.
- Half-Life
- Relatively short; CNS effects may persist due to neurogenic mechanisms
- Short (minutes); gene-regulatory effects are sustained
- Admin Route
- SubQ, Intranasal
- SubQ, Oral
- Research
- —
- —
- Typical Dose
- 200–400 mcg
- 10 mg per day
- Frequency
- Once daily
- Daily for 10–30 days
- Key Benefits
- Rapid-onset antidepressant effects (within 24 hours)
- Promotes hippocampal neurogenesis
- Improves cognitive performance and memory
- Reduces anxiety and depressive behavior
- Novel mechanism — does not act on serotonin/dopamine/GABA receptors directly
- May help treatment-resistant depression
- Neuroprotective effects
- Supports cartilage matrix synthesis and maintenance
- May slow progression of osteoarthritic cartilage degradation
- Reduces chondrocyte apoptosis
- Promotes joint longevity in aging and high-impact sports
- Anti-aging effects on connective tissue
- Complementary to BPC-157 and TB-500 in joint recovery protocols
- Well tolerated in available human and animal research
- Side Effects
- Generally well tolerated in animal models
- Limited human data available
- Possible mild headache or transient mood changes at initiation
- Injection site reactions (SC)
- Generally well tolerated
- Mild injection site reactions
- No significant adverse events reported at standard doses
- Stacks With
- —
- —